Search

Your search keyword '"Callanan, Mary"' showing total 6 results
Start Over Author "Callanan, Mary" Database OpenAIRE
6 results on '"Callanan, Mary"'

1. Flexible Modeling of Net Survival and Cure by AML Subtype and Age: A French Population-Based Study from FRANCIM

Author

Mounier, Morgane, Romain, Gaëlle, Callanan, Mary, Alla, Akoua, Boussari, Olayidé, Maynadié, Marc, Colonna, Marc, Jooste, Valérie, and Network, for FRANCIM

Subjects
Acute promyelocytic leukemia, medicine.medical_specialty, age disparity, Population, lcsh:Medicine, acute myeloid leukemia subtype, Article, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, hemic and lymphatic diseases, medicine, education, Net Survival, neoplasms, education.field_of_study, business.industry, lcsh:R, Not Otherwise Specified, Myeloid leukemia, General Medicine, flexible model, medicine.disease, cure, excess mortality, Population based study, population-based study, 030220 oncology & carcinogenesis, Acute myelomonocytic leukemia, Monocytic leukemia, France, net survival, business, 030215 immunology
Abstract

With improvements in acute myeloid leukemia (AML) diagnosis and treatment, more patients are surviving for longer periods. A French population of 9453 AML patients aged ≥15 years diagnosed from 1995 to 2015 was studied to quantify the proportion cured (P), time to cure (TTC) and median survival of patients who are not cured (MedS). Net survival (NS) was estimated using a flexible model adjusted for age and sex in sixteen AML subtypes. When cure assumption was acceptable, the flexible cure model was used to estimate P, TTC and MedS for the uncured patients. The 5-year NS varied from 68% to 9% in men and from 77% to 11% in women in acute promyelocytic leukemia (AML-APL) and in therapy-related AML (t-AML), respectively. Major age-differenced survival was observed for patients with a diagnosis of AML with recurrent cytogenetic abnormalities. A poorer survival in younger patients was found in t-AML and AML with minimal differentiation. An atypical survival profile was found for acute myelomonocytic leukemia and AML without maturation in both sexes and for AML not otherwise specified (only for men) according to age, with a better prognosis for middle-aged compared to younger patients. Sex disparity regarding survival was observed in younger patients with t-AML diagnosed at 25 years of age (+28% at 5 years in men compared to women) and in AML with minimal differentiation (+23% at 5 years in women compared to men). All AML subtypes included an age group for which the assumption of cure was acceptable, although P varied from 90% in younger women with AML-APL to 3% in older men with acute monoblastic and monocytic leukemia. Increased P was associated with shorter TTC. A sizeable proportion of AML patients do not achieve cure, and MedS for these did not exceed 23 months. We identify AML subsets where cure assumption is negative, thus pointing to priority areas for future research efforts.

Published
2021

2. Ibrutinib, Obinutuzumab And Venetoclax In Relapsed and Untreated Patients with Mantle-Cell Lymphoma, a phase I/II trial

Author

Le Gouill, Steven, Morschhauser, Franck, Chiron, David, Bouabdallah, Krimo, Cartron, Guillaume, Casasnovas, Olivier, Bodet-Milin, Caroline, Ragot, Sylviane, Bossard, Céline, Nadal, Nathalie, Herbaux, Charles, Tessoulin, Benoit, Tchernonog, Emmanuelle, Rossi, Cédric, Mc Culloch, Rory, Gastinne, Thomas, Callanan, Mary, Rule, Simon, Regulation of Bcl2 and p53 Networks in Multiple Myeloma and Mantle Cell Lymphoma (CRCINA-ÉQUIPE 10), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), Groupe de Recherche sur les formes Injectables et les Technologies Associées - ULR 7365 (GRITA), Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), CHU Pessac, Institut de Génétique Moléculaire de Montpellier (IGMM), Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), CHU Dijon, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Université de Bourgogne (UB), Nuclear Oncology (CRCINA-ÉQUIPE 13), Centre hospitalier universitaire de Nantes (CHU Nantes), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Hôpital Saint Eloi (CHRU Montpellier), Lipides - Nutrition - Cancer [Dijon - U1231] (LNC), Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement, Plymouth University, Bernardo, Elizabeth, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Université de Lille, Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM), and CHU Saint-Eloi

Subjects
[SDV.CAN] Life Sciences [q-bio]/Cancer, [SDV.CAN]Life Sciences [q-bio]/Cancer
Abstract

International audience; Ibrutinib, obinutuzumab plus venetoclax demonstrate synergy in pre-clinical models of mantle-cell lymphoma (MCL). OAsIs (NCT02558816), a single-arm multi-center prospective phase I/II trial, aimed to determine the maximum tolerated dose (MTD) of venetoclax in combination with fixed doses of ibrutinib and obinutuzumab, in relapsed MCL patients. At the venetoclax MTD, extension cohorts were opened for relapsed and untreated patients. Safety and efficacy were secondary objectives. Minimal residual disease (MRD) was assessed by allele-specific oligonucleotide-quantitative polymerase chain reaction (ASO-qPCR). Between Oct 14, 2015 to May 29, 2018, forty-eight patients were enrolled. No dose limiting toxicity (DLT) was reported, and venetoclax at 400mg per day was chosen for extension. Eighteen (75%) relapsed and 8 (53%) untreated patients experienced grade 3/4 adverse events (AEs). The complete response rate assessed by positron-emission tomography at the end of cycle 6 was 67% in relapsed and 86.6% in untreated patients. MRD clearance for evaluable patients was seen in 71.5% of relapsed (10 out of 14) and 100% of untreated MRD-evaluable patients (n=12), at the end of three cycles. The median follow-up (mFU) for relapsed patients was 17 months (range, 10 to 35). The 2-years PFS was 69.5% (95% CI, 52.9-91.4%) and 68.6% (95% CI, 49.5-95.1%) for OS. The mFU was 14 months (range, 5 to 19) for untreated patients, the 1-year PFS was 93.3% (95% CI, 81.5-100%). Obinutuzimab, ibrutinib and venetoclax combination is well tolerated and provides high response rates including at the molecular level in relapsed and untreated MCL patients.

Published
2020

3. Identification of a novel BET bromodomain inhibitor-sensitive, gene regulatory circuit that controls Rituximab response and tumour growth in aggressive lymphoid cancers

Author

Emadali, Anouk, Rousseaux, Sophie, Bruder-Costa, Juliana, Rome, Claire, Duley, Samuel, Hamaidia, Sieme, Betton, Patricia, Debernardi, Alexandra, Leroux, Dominique, Bernay, Benoit, Kieffer-Jaquinod, Sylvie, Combes, Florence, Ferri, Elena, Mckenna, Charles, Petosa, Carlo, Bruley, Christophe, Garin, Jérôme, Ferro, Myriam, Gressin, Rémy, Callanan, Mary, Khochbin, Saadi, Laboratoire de Biologie à Grande Échelle (BGE - UMR S1038), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut de Recherche Interdisciplinaire de Grenoble (IRIG), Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Institut d'oncologie/développement Albert Bonniot de Grenoble (INSERM U823), Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-EFS-Institut National de la Santé et de la Recherche Médicale (INSERM), Pôle recherche, Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble, Service d'onco-hématologie et génétique, CHU Grenoble, Department of Chemistry, University of Southern California (USC), Institut de biologie structurale (IBS - UMR 5075 ), Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut de Recherche Interdisciplinaire de Grenoble (IRIG), Service d'hématologie clinique, INSERM U823, équipe 7 (Voies Oncogéniques Des Hémopathies Malignes), Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-EFS-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-EFS-Institut National de la Santé et de la Recherche Médicale (INSERM), INCa-DHOS Translational Research program, 'ARC subvention libre' programs, Fondation de France and Ligue Contre le Cancer, Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut de Recherche Interdisciplinaire de Grenoble (IRIG), and Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre National de la Recherche Scientifique (CNRS)

Subjects
MESH: Cell Differentiation, MESH: Cell Nucleus, MESH: Cell Line, Tumor, cancer-testis factor, MESH: Antigens, CD20, MESH: Gene Expression Profiling, MESH: Protein Structure, Tertiary, immune system diseases, hemic and lymphatic diseases, MESH: Cell Proliferation, CD40, MESH: Animals, MESH: Gene Silencing, CCDC86, MESH: Epigenesis, Genetic, MESH: Mice, SCID, MESH: Mice, MESH: Gene Regulatory Networks, MESH: Lymphoma, B-Cell, Double hit B-cell non-Hodgkin's lymphoma, [SDV.GEN]Life Sciences [q-bio]/Genetics, MESH: Humans, MESH: Proteomics, MESH: Gene Expression Regulation, Neoplastic, MESH: Triazoles, MESH: Antibodies, Monoclonal, Murine-Derived, MESH: Antineoplastic Agents, MESH: Lymphoma, MESH: Azepines, MESH: Neoplasm Transplantation, R- CHOP
Abstract

International audience; Immuno-chemotherapy elicit high response rates in B-cell non-Hodgkin lymphoma but heterogeneity in response duration is observed, with some patients achieving cure and others showing refractory disease or relapse. Using a transcriptome-powered targeted proteomics screen, we discovered a gene regulatory circuit involving the nuclear factor CYCLON which characterizes aggressive disease and resistance to the anti-CD20 monoclonal antibody, Rituximab, in high-risk B-cell lymphoma. CYCLON knockdown was found to inhibit the aggressivity of MYC-overexpressing tumours in mice and to modulate gene expression programs of biological relevance to lymphoma. Furthermore, CYCLON knockdown increased the sensitivity of human lymphoma B cells to Rituximab in vitro and in vivo. Strikingly, this effect could be mimicked by in vitro treatment of lymphoma B cells with a small molecule inhibitor for BET bromodomain proteins (JQ1). In summary, this work has identified CYCLON as a new MYC cooperating factor that autonomously drives aggressive tumour growth and Rituximab resistance in lymphoma. This resistance mechanism is amenable to next-generation epigenetic therapy by BET bromodomain inhibition, thereby providing a new combination therapy rationale for high-risk lymphoma.

Published
2013

4. Identification of a novel BET bromodomain inhibitor-sensitive, gene regulatory circuit that controls Rituximab response and tumour growth in aggressive lymphoid cancers

Author

Emadali, Anouk, Rousseaux, Sophie, Bruder-Costa, Juliana, Rome, Claire, Duley, Samuel, Hamaidia, Sieme, Betton, Patricia, Debernardi, Alexandra, Leroux, Dominique, Bernay, Benoit, Kieffer-Jaquinod, Sylvie, Combes, Florence, Ferri, Elena, Mckenna, Charles, Petosa, Carlo, Bruley, Christophe, Garin, Jérôme, Ferro, Myriam, Gressin, Rémy, Callanan, Mary, Khochbin, Saadi, Duley, Samuel, Laboratoire de Biologie à Grande Échelle (BGE - UMR S1038), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut de Recherche Interdisciplinaire de Grenoble (IRIG), Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Institut d'oncologie/développement Albert Bonniot de Grenoble (INSERM U823), Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-EFS-Institut National de la Santé et de la Recherche Médicale (INSERM), Pôle recherche, Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble, Service d'onco-hématologie et génétique, CHU Grenoble, Department of Chemistry, University of Southern California (USC), Institut de biologie structurale (IBS - UMR 5075 ), Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut de Recherche Interdisciplinaire de Grenoble (IRIG), Service d'hématologie clinique, INSERM U823, équipe 7 (Voies Oncogéniques Des Hémopathies Malignes), Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-EFS-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-EFS-Institut National de la Santé et de la Recherche Médicale (INSERM), and INCa-DHOS Translational Research program, 'ARC subvention libre' programs, Fondation de France and Ligue Contre le Cancer

Subjects
MESH: Cell Differentiation, MESH: Cell Nucleus, MESH: Cell Line, Tumor, cancer-testis factor, MESH: Antigens, CD20, [SDV.GEN] Life Sciences [q-bio]/Genetics, MESH: Gene Expression Profiling, MESH: Protein Structure, Tertiary, immune system diseases, hemic and lymphatic diseases, MESH: Cell Proliferation, CD40, MESH: Animals, MESH: Gene Silencing, CCDC86, MESH: Epigenesis, Genetic, MESH: Mice, SCID, MESH: Mice, MESH: Gene Regulatory Networks, MESH: Lymphoma, B-Cell, Double hit B-cell non-Hodgkin's lymphoma, [SDV.GEN]Life Sciences [q-bio]/Genetics, MESH: Humans, MESH: Proteomics, MESH: Gene Expression Regulation, Neoplastic, MESH: Triazoles, MESH: Antibodies, Monoclonal, Murine-Derived, MESH: Antineoplastic Agents, MESH: Lymphoma, MESH: Azepines, MESH: Neoplasm Transplantation, R- CHOP
Abstract

International audience; Immuno-chemotherapy elicit high response rates in B-cell non-Hodgkin lymphoma but heterogeneity in response duration is observed, with some patients achieving cure and others showing refractory disease or relapse. Using a transcriptome-powered targeted proteomics screen, we discovered a gene regulatory circuit involving the nuclear factor CYCLON which characterizes aggressive disease and resistance to the anti-CD20 monoclonal antibody, Rituximab, in high-risk B-cell lymphoma. CYCLON knockdown was found to inhibit the aggressivity of MYC-overexpressing tumours in mice and to modulate gene expression programs of biological relevance to lymphoma. Furthermore, CYCLON knockdown increased the sensitivity of human lymphoma B cells to Rituximab in vitro and in vivo. Strikingly, this effect could be mimicked by in vitro treatment of lymphoma B cells with a small molecule inhibitor for BET bromodomain proteins (JQ1). In summary, this work has identified CYCLON as a new MYC cooperating factor that autonomously drives aggressive tumour growth and Rituximab resistance in lymphoma. This resistance mechanism is amenable to next-generation epigenetic therapy by BET bromodomain inhibition, thereby providing a new combination therapy rationale for high-risk lymphoma.

Published
2013

5. Accurate hematopoietic stem cell frequency estimates by fitting multicell Poisson models substituting to the single-hit Poisson model in limiting dilution transplantation assays

Author

Bonnefoix, Thierry, Callanan, Mary, INSERM U823, équipe 7 (Voies Oncogéniques Des Hémopathies Malignes), Institut d'oncologie/développement Albert Bonniot de Grenoble (INSERM U823), Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-EFS-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-EFS-Institut National de la Santé et de la Recherche Médicale (INSERM)-Département de cancérologie et d'hématologie, CHU Grenoble-Hôpital Michallon-Hôpital Michallon, and This research is financially supported by ARC (Association pour la Recherche sur le Cancer) grant 3218.

Subjects
[SDV.GEN]Life Sciences [q-bio]/Genetics, MESH: Models, Biological, MESH: Animals, MESH: Mice, MESH: Hematopoietic Stem Cells, MESH: Indicator Dilution Techniques
Abstract

International audience; Limiting dilution transplantation assay (LDTA) is considered as the gold standard method to assess hematopoietic stem cell (HSC) content. Traditionally, HSC frequency estimates are based on the single-hit Poisson model (SHPM), which posits that one donor HSC is sufficient to generate a progeny of detectable differentiated cells above a threshold value in hosts. However, there is no clear support for this statement, and it is receivable that more than one donor HSC may be necessary to provide detectable reconstitution in hosts above the threshold level for detection, usually 0.5% to 1% of donor-derived cells. To address this hypothesis, we evaluated the ability of a class of multiCell Poisson models (C(≥1)PMs) to fit to LDTAs. In 7 of the 8 reanalyzed LDTAs, C(≥1)PMs plausibly compete with the traditional SHPM. Model averaging across the set of plausible models gives 1.32- to 5.88-fold increases in HSC frequencies compared with the SHPM.

Published
2010

6. Accurate hematopoietic stem cell frequency estimates by fitting multicell Poisson models substituting to the single-hit Poisson model in limiting dilution transplantation assays

Author

Bonnefoix, Thierry, Callanan, Mary, INSERM U823, équipe 7 (Voies Oncogéniques Des Hémopathies Malignes), Institut d'oncologie/développement Albert Bonniot de Grenoble (INSERM U823), Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-EFS-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-EFS-Institut National de la Santé et de la Recherche Médicale (INSERM)-Département de cancérologie et d'hématologie, CHU Grenoble-Hôpital Michallon-Hôpital Michallon, This research is financially supported by ARC (Association pour la Recherche sur le Cancer) grant 3218., and Duley, Samuel

Subjects
[SDV.GEN]Life Sciences [q-bio]/Genetics, MESH: Models, Biological, MESH: Animals, [SDV.GEN] Life Sciences [q-bio]/Genetics, MESH: Mice, MESH: Hematopoietic Stem Cells, MESH: Indicator Dilution Techniques
Abstract

International audience; Limiting dilution transplantation assay (LDTA) is considered as the gold standard method to assess hematopoietic stem cell (HSC) content. Traditionally, HSC frequency estimates are based on the single-hit Poisson model (SHPM), which posits that one donor HSC is sufficient to generate a progeny of detectable differentiated cells above a threshold value in hosts. However, there is no clear support for this statement, and it is receivable that more than one donor HSC may be necessary to provide detectable reconstitution in hosts above the threshold level for detection, usually 0.5% to 1% of donor-derived cells. To address this hypothesis, we evaluated the ability of a class of multiCell Poisson models (C(≥1)PMs) to fit to LDTAs. In 7 of the 8 reanalyzed LDTAs, C(≥1)PMs plausibly compete with the traditional SHPM. Model averaging across the set of plausible models gives 1.32- to 5.88-fold increases in HSC frequencies compared with the SHPM.

Published
2010

Catalog

Books, media, physical & digital resources
See catalog results